Bleeding risk was highest with rivaroxaban, lowest with apixaban
Anticoagulation patients at risk for upper gastrointestinal (GI) bleeding saw their risk reduced by more than a third when a proton pump inhibitor (PPI) was added to oral anticoagulant therapy, according to a retrospective analysis of Medicare claims.